YZYifei Zhang

Yifei Zhang

*This is an algorithmically generated author record based on publicly available information.

Yifei Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Zhang

    Department of Central Laboratory, Shenzhen People’s Hospital (The Second Clinical Medical College), Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China (B.Z., J.X., C.Z.).

    1 shared publication
  • Chang Zou

    School of Medicine, Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen 518172, China; Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University), Shenzhen 518020, China

    1 shared publication
  • Jinquan Xia

    Department of Central Laboratory, Shenzhen People’s Hospital (The Second Clinical Medical College), Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518020, China

    1 shared publication
  • Jun Ren

    Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China

    1 shared publication
  • Qijun Zheng

    Jinan University, China

    1 shared publication
  • Xiaoru Li

    Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences and Medicine, Northwest University, Xi’an, Shaanxi, China (Y. Zhou, X.L.).

    1 shared publication

Latest Publications

  • Top Cited Papers

    ACKR1 hi ECs Promote Aortic Dissection Through Adjusting Macrophage Behavior

    by Yayu Wang, Xiong Jia, Yifei Zhang, Bin Zhang, Yazhe Zhou, Xiaoru Li, Xiaoying Zhu, Jinquan Xia, Jun Ren, Chang Zou, et al.

    BACKGROUND: Type A aortic dissection (TAAD) is a life-threatening condition characterized by complex pathophysiology, in which macrophages play a critical but not yet fully understood role. This study focused on the role of endothelial cells with elevated expression of ACKR1 (atypical chemokine receptor 1) and their interaction with proinflammatory macrophages in TAAD development. METHODS: Single-cell transcriptomic analysis of human aortic tissues was used to identify cellular heterogeneity in TAAD. Clinical and animal studies evaluated the relationship between ACKR1 expression and TAAD severity. Gain- and loss-of-function experiments, involving modulation of ACKR1 expression in ECs, investigated its role in macrophage regulation. Molecular docking and in vitro/in vivo studies identified and tested potential drugs targeting ACKR1. RESULTS: TAAD tissues exhibited increased ECs with high ACKR1 expression and proinflammatory macrophages. High ACKR1 levels were strongly associated with TAAD severity. Knockdown of ACKR1 suppressed the NF-κB (nuclear factor-κB) signaling pathway and SPP1 (secreted phosphoprotein 1) expression, reducing macrophage migration and polarization, thereby inhibiting TAAD progression. Conversely, overexpression of ACKR1 exacerbated TAAD. Amikacin, identified as an ACKR1 targeted drug, regulated macrophage behavior via the ACKR1/NF-κB/SPP1 pathway, attenuating TAAD progression and improving survival in mice. CONCLUSIONS: This study reveals how endothelial cells exhibiting high ACKR1 expression modulate macrophage migration and proinflammatory polarization through the ACKR1/NF-κB/SPP1 signaling pathway, a crucial mechanism in TAAD progression. Targeting ACKR1 through both functional and pharmacological approaches effectively suppressed TAAD progression and extended survival in TAAD mice, offering promising new intervention strategies for clinical evaluation.